Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd ADR (NY: CANF )

3.630 +0.490 (+15.61%)
Streaming Delayed Price Updated: 3:41 PM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Can-Fite Biopharma Ltd ADR

< Previous 1 2 3 Next >
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
Via Benzinga
Can Fite Biofarma: Q1 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1... 
Via Benzinga
Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis?
Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced 
Via Benzinga
This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX
Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)... 
Via Benzinga
CAN-FITE ISSUES LETTER TO SHAREHOLDERS
Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,... 
Via Benzinga
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study
Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson... 
Via Benzinga
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Photo by Diana Polekhina on Unsplash 
Via Benzinga
A New Oral Therapy for Psoriasis Could Be Coming Soon
Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice... 
Via Benzinga
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin... 
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:... 
Via Benzinga
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs... 
Via Benzinga
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... 
Via Benzinga
26 Stocks Moving In Wednesday's Mid-Day Session
Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... 
Via Benzinga
CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today
Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around? 
Via InvestorPlace
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
26 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has... 
Via Benzinga
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson... 
Via Benzinga
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the... 
Via Benzinga
RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal
Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill. 
Via InvestorPlace
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.